2014 sales for the benign prostatic hyperplasia (BPH) therapeutics market at approximately $2 billion across the 7MM (US, Germany, France, Italy, Spain, UK and Japan). The US contributed a significant majority of these sales, generating an estimated $1.15 billion over the forecast period, ending in 2024. Benign Prostatic Hyperplasia therapeutics sales in the 7MM are expected to grow to $4.5 billion at a Compound Annual Growth Rate (CAGR) of 8.23%. Browse Full Report With TOC @ http://www.researchmoz.us/opportunityanalyzer-benign-prostatic-hyperplasia-opportunity-analysis-and-forecast-to-2024-report.html
http://www.researchmoz.us/opportunityanalyzer-benign-prostatic-hyperplasia-opportunity-analysis-and-forecast-to-2024-report.html
No comments:
Post a Comment